News

Does the 23andMe Acquisition Make Regeneron a Buy Now?
Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...
The Hudson Independent1d
Regeneron Enters into Agreement to Acquire Consumer Genetics Business
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
Pharmabiz2h
Predictive Oncology breakthrough coincides with Regeneron Pharma’s acquisition of 23andMe for $256 million: Artificial intelligence meets genomics
Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...
MassDevice3d
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...
Zacks Investment Research on MSN15h
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...
Explore more
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer
We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.